Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 19, Issue 3, Pages 639-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2010.03.006
Keywords
Adjuvant endocrine therapy; Tamoxifen; Aromatase inhibitors; Ovarian suppression
Ask authors/readers for more resources
Adjuvant endocrine treatment is an essential component in therapy for hormone receptor positive breast cancer. Among postmenopausal patients, options include tamoxifen, aromatase inhibitors, or a sequence of these agents. Tamoxifen and aromatase inhibitors have distinctive side-effect profiles. Among premenopausal women, tamoxifen remains the standard treatment. The role of ovarian suppression in addition to tamoxifen is under investigation. Questions about the duration of adjuvant endocrine therapy, the use of biomarkers for treatment selection and prognosis, and the management of side effects of adjuvant endocrine therapy remain key areas of investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available